Thymocyte selection-associated high mobility group box gene (TOX) is aberrantly over-expressed in mycosis fungoides and correlates with poor prognosis by Huang, Yuanshen et al.
 
Thymocyte selection-associated high mobility group box gene
(TOX) is aberrantly over-expressed in mycosis fungoides and
correlates with poor prognosis
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Huang, Yuanshen, Ivan V. Litvinov, Yang Wang, Ming-Wan Su,
Ping Tu, Xiaoyan Jiang, Thomas S. Kupper, Jan P. Dutz, Denis
Sasseville, and Youwen Zhou. 2014. “Thymocyte selection-
associated high mobility group box gene (TOX) is aberrantly over-
expressed in mycosis fungoides and correlates with poor
prognosis.” Oncotarget 5 (12): 4418-4425.
Accessed February 16, 2015 9:14:15 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:12785931
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAOncotarget 4418 www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/  Oncotarget, Vol. 5, No. 12
Thymocyte selection-associated high mobility group box gene 
(TOX) is aberrantly over-expressed in mycosis fungoides and 
correlates with poor prognosis 
Yuanshen Huang1,2,3,*, Ivan V. Litvinov4,*, Yang Wang5,*, Ming-Wan Su1,2, Ping Tu5, 
Xiaoyan Jiang3, Thomas S. Kupper6, Jan P. Dutz2,7, Denis Sasseville4 and Youwen 
Zhou1,2,7 
1 Molecular Medicine Lab and Chieng Genomics Centre, Vancouver Coastal Health Research Institute, Vancouver, BC, Canada
2 Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada
3 Terry Fox Laboratory, British Columbia Cancer Agency, and Department of Medical Genetics, University of British Columbia, 
Vancouver, BC, Canada
4 Division of Dermatology, McGill University Health Center, Montreal, QC, Canada
5 Department of Dermatology and Venereology, Peking University First Hospital, Beijing, China
6 Department of Dermatology, Brigham and Women’s Hospital, Harvard Skin Disease Research Center, Harvard University, 
Boston, MA, USA
7 Dermatologic Oncology Program, British Columbia Cancer Agency, Vancouver, BC, Canada
* These authors contributed equally to this work
Correspondence to: Youwen Zhou, email: youwen.zhou@ubc.ca
Correspondence to: Denis Sasseville, email: denis.sasseville@mcgill.ca 
Keywords: TOX, mycosis fungoides, cutaneous T cell lymphoma, marker, prognostic factor
Received: April 2, 2014  Accepted: May 27, 2014  Published: May 28, 2014
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original author and source are credited. 
ABSTRACT
Mycosis fungoides (MF) often mimics the common chronic inflammatory skin 
diseases and is difficult to be diagnosed with certainty, partly because of the lack 
of well-characterized molecular markers. Previously, we discovered that TOX, a 
key T cell development regulator, was aberrantly over-expressed in early stage 
MF. In the current multi-center study involving two independent patient cohorts, 
we determined the prevalence of TOX over-expression in the full spectrum of MF 
skin biopsies, and tested if TOX expression levels correlated with long term clinical 
outcomes. We examined TOX expression levels in 113 MF biopsies. We found that 
the MF biopsies expressed higher TOX mRNA than the controls in both cohorts (17.9 
fold in cohort 1, P = 0.002; 5.8 fold in cohort 2, P < 0.0001). In addition, thicker skin 
lesions such as plaques and tumors expressed even higher TOX levels than thinner 
patches. Further, TOX over-expression differentiated MF from the controls (area under 
the curve [AUC]=0.87, P < 0.0001). Finally, high TOX mRNA levels correlated with 
increased risks of disease progression (P = 0.003) and disease-specific mortality (P 
= 0.008). In conclusion, TOX may be a useful marker for improving MF diagnosis and 
prognostication. 
INTRODUCTION
The incidence of cutaneous T cell lymphoma 
(CTCL) is 6.4 per million and rising, making it the second 
most common extranodal non-Hodgkin lymphomas [1,4]. 
Characterized by clonal accumulation of post-thymic T 
cells residing in the skin [2], CTCL represents a group 
of diseases that are heterogeneous in clinical presentation 
and prognosis. The most common variants are mycosis 
fungoides (MF) and Sézary syndrome (SS), two distinct 
but related diseases, together representing more than 
80% of CTCL[2-4]. In the early disease stages, which Oncotarget 4419 www.impactjournals.com/oncotarget
can last several years, MF presents as flat erythematous 
skin patches resembling benign inflammatory dermatoses 
(BID), such as allergic contact dermatitis, eczema, or 
psoriasis; whereas in the later stages, MF cells gradually 
form plaques or tumors, and may disseminate to the lymph 
nodes and internal organs. The cancerous cells in some 
patients may appear in the peripheral blood, a hallmark of 
the leukemic stage of CTCL[2]. 
At  present,  it  is  difficult  to  accurately  diagnose 
MF. The current approach combines clinic-pathological 
features in three categories: compatible clinical 
presentations, compatible pathologic features, 
and presence of T cell receptor (TCR) gene clonal 
rearrangements (International Society of Cutaneous 
Lymphomas ISCL Criteria, 2005) [5]. However, these 
features are not universally or exclusively present in 
MF. This is particularly true for early stage MF (eMF), 
which has clinical, histological, and even molecular 
(including TCR clonality) resemblance to common benign 
inflammatory  skin  diseases  [5-8].  Further,  eMF  skin 
lesions contain only a small number of malignant cells 
admixed with a large number of reactive CD4+ T cells. As 
a result, diagnostic delays in MF are common, which can 
occasionally exceed a decade. 
Another challenge in MF management is to predict 
long term clinical outcome. While most patients with eMF 
have a life span similar to that of healthy individuals, 9% 
of MF patients with limited patch and/or plaque disease, as 
well as 24% of patients with extensive patches or plaques, 
will experience disease progression. MF patients with end-
stage disease have a high mortality [9, 10]. It is therefore 
critical to identify MF patients with high risk of disease 
progression or disease-specific mortality. However, few 
robust prognostic markers exist for MF, which hinders the 
accurate prediction of disease prognosis. 
In a recent study focusing on gene markers of eMF, 
we identified 19 genes that were highly enriched in eMF 
skin biopsies, compared with benign control biopsies. The 
most enriched gene in eMF biopsies is TOX[11], a critical 
nuclear factor regulating thymocyte lineage commitment. 
The aberrant TOX expression in MF was subsequently 
confirmed in early as well as more advanced disease of 
MF by in a small patient population (N=15)[12]. These 
studies raised the possibility that TOX could be used as a 
marker for MF diagnosis and prognostication. 
The aim of the current study is to test this possibility. 
We examined the expression level of TOX in 113 MF skin 
biopsies from two independent MF cohorts, including 59 
patients for whom long term clinical outcome data, such as 
disease progression and survival, are available. We found 
that TOX was aberrantly over-expressed in the majority 
of MF skin lesions in both cohorts, and that higher TOX 
expression levels correlated with increased risks of disease 
progression and disease-specific mortality.
RESULTS
Demographics of study subjects
A total of 149 individuals contributed skin biopsies, 
including 113 with MF (summarized in Table 1), 25 with 
BID, and 11 with healthy skin (HS).
TOX is ectopically over-expressed in MF skin 
biopsies 
First, TOX mRNA expression in skin biopsies was 
assessed in cohort 1patients, using HS and BID biopsies 
as the controls. Since the levels of TOX mRNA expression 
(mean ± standard error of the mean) of BID were not 
significantly  different  from  those  of  HS  (3.77  ±  0.94 
Table 1: Demographics and clinical characteristics of patients with MF (N=113)
Demographics or Characteristics Cohort 1 
(N=54)
Cohort 2 
(N=59)
Sex
    Male 40 (74%) 36 (61%)
    Female 14 (26%) 23 (39%)
Age at diagnosis (years)
    Median (range) 50 (28-85) 62 (26-91)
Race
    Caucasian 17 (31%) 59 (100%)
    Chinese 31 (57%)
    Other 6 (11%)
Clinical stage
    I 31 (57%) 42 (71%)
    II 16 (30%) 4 (7%)
    III 5 (9%) 5 (8%)
    IV 2 (4%) 8 (14%)Oncotarget 4420 www.impactjournals.com/oncotarget
versus 3.15 ± 1.24, P = 0.70), they were combined to 
form the non-MF controls (3.58 ± 0.75). Compared with 
this, MF cohort 1 had a 17.9 fold increase in TOX gene 
expression (64.21 ± 18.69, P = 0.002) (Figure 1A). 
To evaluate if the TOX over-expression in MF skin 
biopsies is the result of simple increase of CD4+ T cells 
in MF skin biopsies compared with benign controls, TOX 
mRNA level was normalized to CD4 mRNA level in the 
same skin biopsies. In Figure 1B, TOX mRNA to CD4 
mRNA ratios were also much higher (8.7 fold) in MF 
samples, compared with non-MF controls (0.542 ± 0.182 
versus 0.062 ± 0.014, P = 0.011). 
Next, to test if TOX expression varies with tumor 
burden, TOX mRNA levels were plotted according to 
lesional morphological types, such as patches, plaques, 
and tumors. As shown in Figure 1C, skin samples from 
thicker skin lesions of MF, including plaques and tumors, 
expressed higher levels of TOX (74.91 ± 29.72 in plaques 
and 101.3 ± 37.23 in tumors), compared with thinner 
patches (18.31 ± 4.10, P = 0.018). Similarly, TOX/CD4 
ratios displayed an increase in thicker lesions (0.348 ± 
0.065 in plaques and 1.870 ± 1.145 in tumors), compared 
with thinner lesions (0.216 ± 0.055 in patches, P = 0.088, 
Figure 1D). 
To  further  confirm  the  TOX mRNA expression 
increase in MF skin lesions, an independent MF cohort 
(cohort 2) was analyzed. As shown in Figure 1a, TOX 
mRNA in cohort 2 was also much higher than that in non-
MF controls (20.64 ± 3.90 versus 3.58 ± 0.75, P < 0.0001). 
TOX protein is detected in the CD4+ T cell nuclei 
in various MF skin lesions and its levels are in 
parallel with lesional thickness
 To test if TOX protein can be detected in the CD4+ 
T cells of MF lesions, we performed immunofluorescence 
(IF) staining on patch, plaque, and tumor MF biopsies, 
using benign chronic dermatitis (CD) lesions as the 
controls. In line with the TOX mRNA expression results, 
although the CD skin biopsies contained numerous CD4+ T 
cells, few of them had detectable TOX protein expression. 
In contrast, strong nuclear staining of TOX was detected 
in the CD4+ T cells of MF lesions. In addition, thicker MF 
skin lesions   (plaque and tumor types) displayed stronger 
TOX staining than patch lesions (Figure 2).
High TOX mRNA levels differentiate MF from 
non-MF skin biopsies
We next applied receiver operating characteristic 
(ROC) curve to evaluate if increased TOX mRNA levels 
Figure 1: TOX mRNA levels are increased in MF skin biopsies. (A) TOX mRNA in MF samples compared with BID and HS. **, 
P = 0.002, ***, P < 0.0001. (B) The ratios of TOX mRNA/CD4 mRNA in samples of MF, BID and HS. *, P = 0.011. (C) TOX mRNA in 
different types of MF lesions. *, P = 0.018. (D) The ratios of TOX mRNA/CD4 mRNA in different types of MF lesions. Horizontal bars 
denote the mean and standard error of mean for each sample type analyzed. Two tailed t tests were used for comparison. NS=not significant.Oncotarget 4421 www.impactjournals.com/oncotarget
could differentiate MF from non-MF controls. As shown 
in Figure 3, TOX mRNA levels had good discriminatory 
power for MF, demonstrated by an area under the curve 
(AUC) value of 0.87 (95% confidence interval (CI) =0.81-
0.94, P < 0.0001, Figure 3A). When cutoff was set at 2.99, 
TOX  mRNA  levels  had  90.3%  sensitivity  and  75.0% 
specificity for MF. 
Given that early MF is most difficult to diagnose 
in the clinical practice, ROC curve was further plotted 
in stage-I MF (N=73). TOX mRNA levels had an AUC 
of 0.85 (95% CI = 0.77-0.93, P < 0.0001, Figure 3B) for 
stage-I MF, with a sensitivity of 86.3% and a specificity of 
75.0% at the cutoff of 2.99. 
High  TOX  mRNA  levels  define  a  group  of 
MF patients with increased risks of disease 
progression and disease-specific mortality 
To test if TOX expression in MF skin biopsies 
influences  disease  progression  and  disease-specific 
mortality, we evaluated MF cohort 2, for whom clinical 
outcome data are available for up to 6 years (median 
follow up time = 45 months). Kaplan-Meier curves 
showed that high TOX mRNA levels in skin biopsies were 
associated with much increased likelihood of disease 
progressing into a higher clinical stage during the follow 
up period (P = 0.003, Figure 4A). Meanwhile, those 
cases with low TOX expression had very low tendency to 
progress clinically during the follow up period. Through 
multivariate testing, we found that high TOX expression 
remained significantly associated with disease progression, 
after adjusting for stage, age, and sex (hazard ratio (HR) = 
2.62, P = 0.028, Table 2). 
Table 2: Multivariate analyses of prognostic factors in MF disease progression and disease-specific mortality 
Prognostic factor
Progression Disease-specific mortality
HR 95.0% CI P HR 95.0% CI P
TOX 2.62 1.1 to 6.2 0.028 6.16 1.2 to 30.8 0.027
Stage 3.57 1.6 to 7.9 0.002 5.31 1.2 to 23.5 0.028
Age 1.02 1.0 to 1.0 0.246 1.00 1.0 to 1.0 0.989
Sex 1.02 0.5 to 2.3 0.960 0.55 0.1 to 2.1 0.386
Figure 2: Ectopic TOX protein is detected in CD4+ T 
lymphocytes in MF skin lesions, but absent in BID. 
BID (shown here is CD) and MF skin biopsies were stained 
with antibodies against TOX (red, Alexa Fluor® 594) and CD4 
(green, Alexa Fluor® 488). DAPI was used to stain the nuclei of 
cells. Insets: magnification from representative areas. Bars=20 
μm. 
Figure 3: Increased TOX mRNA levels differentiate 
MF from non-MF biopsies. (A) ROC analysis on the MF 
biopsies as a whole (N=113) and non-MF skin biopsies (N=36). 
(B) ROC analysis on the stage-I MF biopsies (N=73) and non-
MF skin biopsies (N=36). AUC=Area under the curve.Oncotarget 4422 www.impactjournals.com/oncotarget
In addition, high TOX mRNA levels were strongly 
associated  with  increased  disease-specific  mortality 
(P = 0.008, Figure 4B) in MF patients. Multivariate 
analysis showed that high TOX mRNA expression was an 
independent predictor of worse survival after adjusting for 
other variables (HR = 6.16, P = 0.027, Table 2), including 
clinical stage, age and sex. 
 Collectively, these findings supported that high 
TOX mRNA levels defined a subset of MF patients with 
increased risks of disease progression and disease-specific 
mortality. 
DISCUSSION
The earliest evidence of aberrant TOX expression 
in MF came from our previous transcriptome analysis 
focusing on eMF, which showed that eMF CD4+ T cells, 
but not CD4+ T cells in BID, over-expressed TOX at both 
mRNA level and protein level[11]. 
TOX encodes a nuclear protein of the high-mobility 
group (HMG) box superfamily. It contains a DNA-
binding domain, which allows it to regulate transcription 
by modifying local chromatin structure and modulating 
the formation of multi-protein complexes [13, 14]. In 
mouse models, TOX was reported to be essential for the 
proper development of CD4+ thymocyte [13, 15]. Tightly 
controlled  in  a  stage-specific  manner  in  developing 
thymocytes, TOX is down-regulated before T cells exit 
the thymus, and remains suppressed in the peripheral 
lymphoid tissues [13]. Despite its rapid induction by pre-
TCR and TCR signalling in immature thymocytes, TOX 
is not induced by TCR signalling in mature T cells[13]. 
Hence its up-regulation in eMF lesional CD4+ T cells is 
unlikely to be a result of T cell activation. Rather, this 
unusual observation led us to propose that TOX is a disease 
marker with diagnostic and/or prognostic value for MF. 
This study tested and confirmed our hypothesis. 
Our  findings  not  only  confirmed  TOX expression in 
eMF, but also demonstrated that TOX ectopic expression 
is a common feature across the entire spectrum of MF. 
Moreover, high TOX mRNA levels effectively differentiate 
MF, both as a whole and for stage-I MF alone, from 
benign inflammatory or healthy skin. Finally, high TOX 
expression strongly correlated with worse prognosis, 
including increased disease progression and disease-
specific mortality. 
MF clinically resembles the far more common, but 
clinically benign skin inflammatory diseases such as CD, 
psoriasis, and cutaneous reactions to drugs. Differentiating 
MF from these benign conditions is difficult, largely due to 
the lack of well-defined molecular markers in the clinical 
setting. Although CD2, CD3, CD5, and CD7 deficiency 
is included in ISCL criteria to define early MF, the loss of 
CD2, CD3, and/or CD5 in T cells is only 10% sensitive, 
despite  its  100%  specificity.  CD7  deficiency  is  about 
40% sensitive and 80% specific in general [5]. Therefore 
better markers with higher sensitivity and specificity are 
needed. Although a small number of markers have been 
reported for MF skin biopsies, including loss of CD13, 
ectopic expression of BLK gene, microRNAs (including 
miR-155, miR-203 and miR-205) [16-18], BCL7A loss 
[19, 20], enhanced AHI1 [21], and CD158K/ KIR3DL2 in 
transformed advanced MF [22], few of these markers were 
tested in multicenter studies, or used in a clinical setting. 
Similarly, achieving accurate prognostication of 
MF patients is challenging clinically. Several molecular 
markers have been described to be of potential prognostic 
value. For MF prognosis, persistence of the same CD4+ 
T cell clone over time in skin biopsies correlated with an 
aggressive disease course[23]. Loss of BCL7A expression 
predicted aggressive disease course in patients with 
early stage CTCL [20]. Specifically for tumor stage MF, 
presence of chromosomal alterations on 9p21, 8q24, 
10q26qter and 1q21-1q22 often indicates a poor prognosis 
[24, 25]. The clinical utility of these markers needs further 
evaluation in larger studies. 
Figure 4: Higher TOX mRNA levels correlate with 
worse clinical outcome. (A) Kaplan-Meier plot showing the 
relationship between TOX mRNA levels and disease progression 
in MF patients. (B) The relationship between TOX mRNA levels 
and disease-specific mortality in MF patients. Oncotarget 4423 www.impactjournals.com/oncotarget
In light of these, the current multicenter study 
consisting of patients with diverse ethnic origins 
demonstrated considerable potential of TOX to improve 
management for MF. Kaplan-Meier curve analysis 
demonstrated that MF lesions, including early MF lesions, 
that contain no or low TOX mRNA expression had little 
tendency of disease progression or MF-related death. TOX 
as a marker can identify these low-risk patients for whom 
conservative management perhaps would be adequate 
rather than being subjected to more toxic treatments, such 
as topical nitrogen mustard, or carmustine. In contrast, MF 
patients with high levels of TOX expression may benefit 
from early and more aggressive treatment to prevent 
disease progression and to reduce MF-related mortality. 
Despite the predictive potential of TOX for MF 
demonstrated in this study, caution needs to be taken 
while interpreting its clinical usefulness. Due to the rarity 
of this disease, only a moderate sample size of 113 can 
be reached from three study centres from three countries. 
Additional  confirmation  in  other  centres  is  warranted 
to uncover the true clinical relevance of TOX for MF 
diagnosis and prognostication. 
Notwithstanding this limitation, the multicenter 
nature of our study underscores the consistency of TOX 
up-regulation in patients from diverse ethnical and 
geographic backgrounds. Furthermore, TOX as a marker 
is highly robust and user-friendly, since it can be detected 
by a number of routine dermatopathologic tools, such as 
qPCR, IF, and immunohistochemistry staining. 
Given  TOX’s critical regulatory role in CD4+ T 
cell development and its aberrant over-expression in 
the majority of MF skin lesion, it is highly likely that 
TOX activation plays a pathogenic role in MF. Further 
studies are therefore warranted to evaluate if TOX ectopic 
expression contributes to the development of MF. If 
proven to be true, TOX may emerge as a novel therapeutic 
target for MF in the future. 
In summary, TOX ectopic expression is readily 
and frequently detected in the malignant CD4+ T cells in 
MF skin biopsies, including the most challenging eMF. 
Moreover, increased TOX expression levels define a group 
of MF patients with increased risk of disease progression 
and disease-specific mortality. Therefore, characterization 
of TOX expression status of MF patients may be valuable 
not only for diagnostic confirmation but also for guiding 
MF management in the future.
MATERIALS AND METHODS
Study subject recruitment
With approval from institutional clinical ethics 
board, this study was conducted according to Declaration 
of Helsinki Principles, and all participants has provided 
their written informed consent. Two MF cohorts 
were examined in this study (Table 1). Cohort 1 was 
prospectively recruited from Vancouver Canada and 
Beijing China from 2008-2012, including 54 subjects with 
MF (cohort 1, N=54) recruited from the Skin Lymphoma 
Clinics of British Columbia Cancer Agency (BCCA, 
Vancouver, Canada, N=26), and Peking University 
First Hospital (Beijing, China, N=28). In addition, 25 
individuals with BID (9 psoriasis, 13 CD, and 3 pityriasis 
rubra pilar) and 11 volunteers with HS were recruited 
from the outpatient dermatology clinic of University of 
British Columbia (UBC, Vancouver, Canada). Cohort 2 of 
MF patients (cohort 2, N=59) was collected from Harvard 
University with institutional approval and had been well-
characterized previously[20, 21, 26, 27]. The diagnosis 
and clinical staging were established according to the 
diagnostic criteria of CTCL[7]. 
Preparation of clinical samples and analyses of 
TOX mRNA and protein 
Obtaining skin biopsies, RNA extraction, and 
quantitative reverse transcription-polymerase chain 
reaction (qPCR) were performed using protocols that were 
previously described [11]. Beta actin (ACTB) mRNA was 
used as the internal control. The results were expressed as 
copies of TOX mRNA per 1000 copies of ACTB mRNA. 
In addition, TOX protein in MF and control skin biopsies 
was analyzed by IF using specific antibodies against TOX 
(rabbit anti-TOX polyclonal antibody, Sigma-Aldrich, St. 
Louis, MO) and human CD4 protein (mouse monoclonal 
anti-human CD4 antibody, Dako, Denmark), as previously 
described [11]. Cell nuclei were counterstained with 
4’ 6-diamidino-2-phenylindole (DAPI). The slides 
were visualized under a Zeiss AxioVert 200M inverted 
fluorescence microscope (Carl Zeiss AG, Jena, Germany). 
Representative sections of the micrographs were obtained 
and processed with the Zeiss AxioVision 4.8 image 
acquisition and processing software (Carl Zeiss AG). 
Brightness and contrast were adjusted consistently across 
all images. 
Statistical analyses 
SPSS 14 (Chicago, IL), GraphPad Prism 5.00 (San 
Diego, CA), and X-Tile (New Haven, CT) were used for 
statistical analyses. P values < 0.05 were considered to be 
statistically significant.
Continuous variables were compared by two-tailed t 
tests. ROC method was used to analyze the sensitivity and 
specificity of TOX mRNA levels to differentiate MF from 
BID or HS skin biopsies. 
X-Tile software, a marker cutpoint analysis 
tool developed by Camp RL et al[28], was applied to 
determine the optimal cut-point for TOX  expression Oncotarget 4424 www.impactjournals.com/oncotarget
level as 8.2 (Miller-Siegmund corrected P value=0.027). 
In our analysis of disease progression and disease-
specific mortality, TOX high and TOX low groups were 
defined by the expression levels higher or lower than 8.2, 
respectively.
MF patients were considered to experience disease 
progression when disease progressed to more advanced 
clinical stages (i.e. beyond stage I) and/or death due to MF 
during the follow up period[20]. Individuals with multiple 
progressions (n > 1) were counted as n progression events. 
Survival time was defined as the duration from the date of 
sample collection to death. 
Disease progression and disease-specific mortality 
rates were assessed using the Kaplan-Meier curves. 
Univariate analysis using the log-rank test was first used 
to detect any association between TOX mRNA level 
and disease progression and disease-specific mortality. 
Multivariate analyses using COX proportional hazards 
regression were then used to evaluate the following 
prognostic factors: stage at diagnosis (stages I and II 
versus stages III and IV), TOX mRNA level, age, and sex. 
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